Healthcare provider profile · identity verified

James Kos, MD

Internal Medicine · FT LAUDERDALE, FL · NPI 1053406207

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	439	102
Eliquis	Apixaban	363	65
Losartan Potassium	Losartan Potassium	319	71
Levothyroxine Sodium	Levothyroxine Sodium	303	62
Amlodipine Besylate	Amlodipine Besylate	287	61
Gabapentin	Gabapentin	234	49
Potassium Chloride	Potassium Chloride	202	39
Metoprolol Tartrate	Metoprolol Tartrate	186	46
Lisinopril	Lisinopril	183	39
Tamsulosin Hcl	Tamsulosin Hcl	179	45
Quetiapine Fumarate	Quetiapine Fumarate	153	57
Hydrochlorothiazide	Hydrochlorothiazide	127	27
Clopidogrel	Clopidogrel Bisulfate	125	35
Famotidine	Famotidine	125	43
Furosemide	Furosemide	121	39
Metoprolol Succinate	Metoprolol Succinate	118	30
Mirtazapine	Mirtazapine	116	30
Pantoprazole Sodium	Pantoprazole Sodium	114	42
Trazodone Hcl	Trazodone Hcl	111	36
Sertraline Hcl	Sertraline Hcl	108	22
Donepezil Hcl	Donepezil Hcl	102	24
Metformin Hcl	Metformin Hcl	99	25
Nifedipine Er	Nifedipine	91	18
Latanoprost	Latanoprost	90	15
Omeprazole	Omeprazole	88	31
Memantine Hcl	Memantine Hcl	82	26
Carvedilol	Carvedilol	76	19
Finasteride	Finasteride	75	17
Divalproex Sodium	Divalproex Sodium	71	13
Simvastatin	Simvastatin	70	22
Spironolactone	Spironolactone	70	15
Carbidopa-Levodopa	Carbidopa/Levodopa	69	17
Prednisone	Prednisone	68	20
Allopurinol	Allopurinol	66	12
Escitalopram Oxalate	Escitalopram Oxalate	66	24
Bumetanide	Bumetanide	64	13
Lorazepam	Lorazepam	64	41
Fiasp Flextouch	Insulin Aspart (Niacinamide)	61	11
Duloxetine Hcl	Duloxetine Hcl	57	16
Hydralazine Hcl	Hydralazine Hcl	55	17
Entresto	Sacubitril/Valsartan	52	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	51	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	50	42
Cephalexin	Cephalexin	49	36
Risperidone	Risperidone	49	14
Temazepam	Temazepam	48	14
Levetiracetam	Levetiracetam	41	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	41	21
Xarelto	Rivaroxaban	41	suppressed
Fluticasone Propionate	Fluticasone Propionate	40	17
Montelukast Sodium	Montelukast Sodium	39	12
Baclofen	Baclofen	38	suppressed
Labetalol Hcl	Labetalol Hcl	38	11
Digoxin	Digoxin	35	suppressed
Amiodarone Hcl	Amiodarone Hcl	32	suppressed
Lamotrigine	Lamotrigine	32	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	32	11
Lactulose	Lactulose	31	12
Atenolol	Atenolol	30	suppressed
Morphine Sulfate	Morphine Sulfate	29	29
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	28	17
Glyxambi	Empagliflozin/Linagliptin	26	suppressed
Ingrezza	Valbenazine Tosylate	26	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	25	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	25	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Fenofibrate	Fenofibrate,micronized	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Alprazolam	Alprazolam	24	suppressed
Humalog Kwikpen U-100	Insulin Lispro	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Azithromycin	Azithromycin	21	16
Buspirone Hcl	Buspirone Hcl	21	11
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	20	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Novolog	Insulin Aspart	19	suppressed
Tramadol Hcl	Tramadol Hcl	18	11
Primidone	Primidone	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	suppressed
Vilazodone Hcl	Vilazodone Hcl	17	suppressed
Calcium Acetate	Calcium Acetate	16	suppressed
Glipizide	Glipizide	16	suppressed
Midodrine Hcl	Midodrine Hcl	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Pyridostigmine Bromide	Pyridostigmine Bromide	15	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	14	suppressed
Fentanyl	Fentanyl	14	suppressed
Lithostat	Acetohydroxamic Acid	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Meropenem	Meropenem	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Rivastigmine	Rivastigmine	13	suppressed
Valsartan	Valsartan	13	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Fluorometholone	Fluorometholone	12	suppressed
Gemtesa	Vibegron	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Novolin R	Insulin Regular, Human	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Megestrol Acetate	Megestrol Acetate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error